Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Burning Rock Biotech (BNR) over the last 6 years, with Q3 2025 value amounting to $65.2 million.

  • Burning Rock Biotech's Cash & Equivalents fell 814.97% to $65.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.2 million, marking a year-over-year decrease of 814.97%. This contributed to the annual value of $71.2 million for FY2024, which is 1780.94% down from last year.
  • Per Burning Rock Biotech's latest filing, its Cash & Equivalents stood at $65.2 million for Q3 2025, which was down 814.97% from $63.2 million recorded in Q2 2025.
  • In the past 5 years, Burning Rock Biotech's Cash & Equivalents ranged from a high of $318.3 million in Q1 2021 and a low of $63.2 million during Q2 2025
  • In the last 5 years, Burning Rock Biotech's Cash & Equivalents had a median value of $101.0 million in 2023 and averaged $135.4 million.
  • Per our database at Business Quant, Burning Rock Biotech's Cash & Equivalents soared by 1210639.54% in 2021 and then crashed by 4336.07% in 2022.
  • Quarter analysis of 5 years shows Burning Rock Biotech's Cash & Equivalents stood at $185.8 million in 2021, then dropped by 29.36% to $131.3 million in 2022, then tumbled by 34.01% to $86.6 million in 2023, then fell by 17.79% to $71.2 million in 2024, then fell by 8.48% to $65.2 million in 2025.
  • Its Cash & Equivalents stands at $65.2 million for Q3 2025, versus $63.2 million for Q2 2025 and $68.2 million for Q1 2025.